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Colorectal cancerAbstract Objective: To investigate the cost-effectiveness of panitumumab plus mFOLFOX6
(oxaliplatin, 5-ﬂuorouracil and leucovorin) compared with bevacizumab plus mFOLFOX6 in
ﬁrst-line treatment of patients with wild-type RAS metastatic colorectal cancer (mCRC).
Design: A semi-Markov model was constructed from a French health collective perspective,
with health states related to ﬁrst-line treatment (progression-free), disease progression with
and without subsequent active treatment, resection of metastases, disease-free after successful
resection and death.
Methods: Parametric survival analyses of patient-level progression-free and overall survival
data from the only head-to-head clinical trial of panitumumab and bevacizumab (PEAK)
were performed to estimate transitions to disease progression and death. Additional data from
PEAK informed the amount of each drug consumed, duration of therapy, subsequent therapy
use, and toxicities related to mCRC treatment. Literature and French public data sources were
used to estimate unit costs associated with treatment and duration of subsequent active ther-
apies. Utility weights were calculated from patient-level data from panitumumab trials in the
ﬁrst-, second- and third-line settings. A life-time perspective was applied. Scenario, one-way,
and probabilistic sensitivity analyses were performed.919 541
mgren),
2792 C.N. Graham et al. / European Journal of Cancer 50 (2014) 2791–2801Results: Based on a head-to-head clinical trial that demonstrates better efﬁcacy outcomes for
patients with wild-type RAS mCRC who receive panitumumab plus mFOLFOX6 versus
bevacizumab plus mFOLFOX6, the incremental cost per life-year gained was estimated to
be €26,918, and the incremental cost per quality-adjusted life year (QALY) gained was
estimated to be €36,577. Sensitivity analyses indicate the model is robust to alternative
parameters and assumptions.
Conclusions: The incremental cost per QALY gained indicates that panitumumab plus
mFOLFOX6 represents good value for money in comparison to bevacizumab plus
mFOLFOX6 and, with a willingness-to-pay ranging from €40,000 to €60,000, can be consid-
ered cost-effective in ﬁrst-line treatment of patients with wild-type RAS mCRC.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).1. Introduction
Colorectal cancer (CRC) represents a signiﬁcant
social and healthcare burden. It is the second most com-
mon cancer in Europe, with an estimated 447,000 new
cases occurring in 2012, and is also the second most
common cause of cancer death in Europe, accounting
for an estimated 215,000 deaths in 2012 [1]. In France,
CRC is the third most common cancer in men and the
second in women with incidence rates comparable to
those found in other high-risk areas of Western Europe,
North America, Australia/New Zealand and Japan [2].
Of patients with CRC, 20–25% have metastatic dis-
ease (mCRC) at diagnosis, and metastases eventually
develop in up to 50% of all patients [3]. Patients with
mCRC experience signiﬁcant morbidity and diminished
quality of life. The 5-year relative survival rate is only
5–15% in patients with widespread metastatic disease,
indicating that there is a need to improve treatment
outcomes [4]. Although the goal of treatment for most
patients with mCRC is to prolong survival for as long
as possible while maintaining quality of life, surgical
resection of metastases can achieve cure for a small
proportion of patients [5].
According to the European Society for Medical
Oncology (ESMO) clinical practice guidelines for
advanced CRC, panitumumab and cetuximab,
monoclonal antibodies against the epidermal growth
factor receptor (EGFR), and bevacizumab, which binds
the vascular endothelial growth factor (VEGF), can be
considered in combination with chemotherapy as ﬁrst-
line options for selected patients with mCRC [6]. The
ESMO recommendations are based on the improved
outcomes reported for these biologics versus chemother-
apy alone in clinical trials.
While panitumumab and bevacizumab are recom-
mended options in ﬁrst-line treatment of patients with
mCRC, additional evidence (e.g. a head-to-head clinical
trial) and updated labels for the EGFR inhibitors should
be considered when deciding between EGFR- and
VEGF-targeted treatments. Since the initial European
Medicines Agency (EMA) approval of panitumumab in
2007, identiﬁcation of additional RASmutations beyondKRAS exon 2 (i.e. mutations in KRAS exons 3 and 4 and
NRAS exons 2, 3, and 4) predicts lack of response to
panitumumab in combination with oxaliplatin-based
chemotherapy, and has driven new labels for the EGFR
inhibitors. Use of the extended RAS biomarker selection
reduces the patient population eligible to receive
panitumumab by approximately 17% compared with
the wild-type KRAS exon 2 mCRC population, and
improves the eﬃcacy of panitumumab without altering
its safety proﬁle [7]. The European Committee for
Medicinal Products for Human Use (CHMP) stated
recently that the beneﬁt/risk balance of panitumumab
has improved in its newly approved wild-type RAS indi-
cations due to the exclusion of patients with additional
RAS mutations outside those initially investigated in
the KRAS exon 2 analyses.
Moreover, data from a prospective-retrospective
analysis of the phase II PEAK trial (NCT00819780) of
panitumumab versus bevacizumab in ﬁrst-line mCRC
have recently been reported [8,9]. The PEAK trial is
an open-label, randomised, multicenter clinical study
designed to compare head-to-head panitumumab plus
oxaliplatin, 5-ﬂuorouracil and leucovorin (mFOL-
FOX6) (n = 142) versus bevacizumab plus mFOLFOX6
(n = 143). Results from patients with wild-type RAS
mCRC, as deﬁned by the extended RAS analysis
(n = 88 for panitumumab plus mFOLFOX6; n = 82
for bevacizumab plus mFOLFOX6), showed a statisti-
cally signiﬁcant incremental progression-free survival
(PFS) beneﬁt of 2.9 months (p = 0.03) and a strong
trend in terms of overall survival (OS) incremental ben-
eﬁt (12.4 months) favouring the panitumumab arm [8,9].
In such a context of improved beneﬁt/risk balance of
panitumumab, a legitimate question arises regarding the
relative value for money of panitumumab versus bev-
acizumab given the healthcare costs challenges faced in
France and in Europe generally. To our knowledge only
one cost-eﬀectiveness manuscript has been published
comparing panitumumab versus bevacizumab in ﬁrst-
line mCRC, but it is of limited relevance because it is
constrained to an outdated label population (wild-type
KRAS) and it does not make use of the informative data
from the PEAK trial [10].
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tumumab versus bevacizumab in the wild-type RAS set-
ting, which is consistent with current labels for EGFR
inhibitors in mCRC, we developed a semi-Markov
model based on the PEAK clinical trial conducted in
patients with wild-type RAS mCRC in the ﬁrst-line set-
ting, and applied a French health collective perspective.
2. Methods
2.1. Population
The model population was based on a subset of the
patient population from PEAK, the only ﬁrst-line clinical
trial of panitumumab plus mFOLFOX6 versus bev-
acizumab plus mFOLFOX6 conducted in patients with
mCRC. This subset population was deﬁned as adults
(ageP 18 years) who have been diagnosed with wild-type
RAS (i.e. no mutation in exons 2, 3, or 4 of KRAS and
NRAS) mCRC and who have not previously been treated
with chemotherapy or investigational agents for mCRC.
2.2. Model structure
A semi-Markov model structure was selected to assess
the cost-eﬀectiveness of panitumumab plus mFOLFOX6
relative to bevacizumab plus mFOLFOX6 in the ﬁrst-
line treatment of patients with mCRC. This approach
was similar to cost-eﬀectiveness models of mCRC and
other metastatic and/or advanced cancers found in the
literature [11–14]. The model uses a 2-week cycle length;
the time horizon is that of the lifetime of a patient with
mCRC (which is assumed to be no more than 20 years
post treatment initiation). The model begins with a
cohort of patients initiating ﬁrst-line mCRC treatment
and concludes when the entire patient cohort has died.
The semi-Markov model structure and allowed transi-
tions between health states are presented in Fig. 1.
2.3. Transition probabilities
Transition probabilities to disease progression and
death for panitumumab plus mFOLFOX6 and bev-
acizumab plus mFOLFOX6 were based on parametric
survival curves estimated in a patient-level analysis of
PFS and OS from the PEAK clinical trial. The paramet-
ric survival modelling was coded in SAS (version 9.3;
Cary, NC) using the LIFEREG procedure. Parametric
survival curves were estimated using exponential, Wei-
bull and log-logistic statistical distributions for each
treatment. The PFS Kaplan–Meier plot and the ﬁtted
PFS curves for panitumumab plus mFOLFOX6 and
bevacizumab plus mFOLFOX6 are displayed in Fig. 2.
The OS Kaplan–Meier plot and the ﬁtted OS curves
for panitumumab plus mFOLFOX6 and bevacizumab
plus mFOLFOX6 are displayed in Fig. 3. The Weibull
distribution was selected as the best-ﬁtted curve for bothPFS and OS based on graphical overlay of the curves
and the Kaplan–Meier plot, goodness-of-ﬁt statistics
(Akaike information criterion) and face validity of
long-term survival projections.
Resection-related transition probabilities were based
on data from the PEAK clinical trial and used to model
the number of resection attempts, the probability that
an attempt results in complete removal or reduction of
the tumour, and the mean time to resection for patients
with wild-type RAS mCRC. Disease-free survival and
OS for patients with a successful resection were mod-
elled using parametric survival modelling and data from
a study describing a population of patients with mCRC
that was initially unresectable, but became resectable
after chemotherapy [15].
Following disease progression, patients could be trea-
ted with an active subsequent treatment (modelled treat-
ments were anti-EGFR treatment plus FOLFIRI,
bevacizumab plus FOLFIRI) or best supportive care
(BSC), with distribution of active treatment or BSC taken
from data from the PEAK clinical trial. Based on clinical
guidelines from the National Comprehensive Cancer Net-
work, patients switched to second-line therapy of a diﬀer-
ent class (e.g. anti-EGFR to anti-VEGF and vice versa)
[16,17]. The length of therapy for active second-line treat-
ment was deﬁned by the treatment’s PFS in second-line
treatment, as reported in the published literature, as this
information was not collected in the PEAK trial. The
median active second-line treatment PFS was converted
to an estimated mean PFS by assuming an exponential
distribution. Following disease progression on any subse-
quent active treatment, patients were treated with BSC
until death. Second-line therapies did not directly aﬀect
OS, as it was referenced to the OS as observed in the
PEAK trial, but they inﬂuenced costs and quality of life.
Transition probabilities from subsequent active ther-
apy to BSC were calculated from the weighted average
PFS of each subsequent therapy modelled; transition
probabilities to death were calculated from the selected
best-ﬁtting OS curve; and the transition probability
from the progression-free health state to the health state
Progressive Disease: Treat With Subsequent Active
Therapy was calculated by multiplying the transition
probability to disease progression in each cycle by the
percentage of patients receiving active second-line treat-
ment. Similarly, the transition probability to the health
state Progressive Disease: Treat With BSC was calcu-
lated by multiplying the transition probability to disease
progression in each cycle by the percentage of patients
receiving BSC (1 minus the percentage of patients
receiving active second-line treatment).
2.4. Costs
Drug-acquisition costs were calculated from costs
using French Health National Insurance [18,19], using
2013 costs. Consumption of drugs, deﬁned as the
Fig. 1. Model structure. BSC, best supportive care; mCRC, metastatic colorectal cancer. Health-states transition probability sources: 1aProgression
Free to Progressive Disease: Treat With Subsequent Active Therapy (source: parametric survival modelling of patient-level data [i.e. progression-
free survival]; percentage of patients utilising active treatment postprogression from PEAK trial). 1bProgression Free to Progressive Disease: Treat
With BSC (source: parametric survival modelling of patient-level data [i.e. progression-free survival]; percentage of patients utilising BSC
postprogression from PEAK trial). 2Progression Free to Death (source: parametric survival modelling of patient-level data from PEAK trial [i.e.
overall survival]). 3Progression Free to Attempted Resection of Metastases (source: percentage of patients undergoing resection attempt from
PEAK trial). 4Attempted Resection of Metastases to Progression Free (source: percentage of patients with failed resection attempt from PEAK
trial). 5Progressive Disease: Treat With Subsequent Active Therapy to Death (source: parametric survival modelling of patient-level data from
PEAK trial [i.e. overall survival]). 6Progressive Disease: Treat With BSC to Death (source: parametric survival modelling of patient-level data from
PEAK trial [i.e. overall survival]). 7Attempted Resection of Metastases to Disease Free After Metastases Resection (source: percentage of patients
with successful resection attempt from PEAK trial). 8Disease Free After Metastases Resection to Progressive Disease: After Resection and Relapse
(source: parametric survival modelling of progression-free survival data from Adam et al. [15]). 9Disease Free After Metastases Resection to Death
(source: parametric survival modelling of overall survival data from Adam et al. [15]). 10Progressive Disease: After Resection and Relapse to Death
(source: parametric survival modelling of overall survival data from Adam et al. [15]). 11Progressive Disease: Treat With Subsequent Active
Therapy to Progressive Disease: Treat With BSC (source: weighted average of published progression-free survival values for second-line treatment
options).
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Fig. 2. Progression-free survival Kaplan–Meier plot and ﬁtted curves.
Bmab, bevacizumab; Exp, exponential; FOLFOX, leucovorin, 5-
ﬂuorouracil, and oxaliplatin; KM, Kaplan–Meier; Pmab, pani-
tumumab. Akaike information criterion for goodness-of-ﬁt: Wei-
bull = 359.46, exponential = 390.42; log–logistic = 360.44.
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Fig. 3. Overall survival Kaplan–Meier plot and ﬁtted curves. Bmab,
bevacizumab; Exp, exponential; FOLFOX, leucovorin, 5-ﬂuorouracil,
and oxaliplatin; KM, Kaplan–Meier; Pmab, panitumumab. Akaike
information criterion for goodness-of-ﬁt: Weibull = 348.29, exponen-
tial = 350.65; log–logistic = 352.60.
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per patient, and the average number of cycles adminis-
tered were calculated from data in the PEAK clinicaltrial for direct treatment comparators. Drug-acquisition
costs and drug-consumption inputs are presented in
Table 1, along with sources and assumptions. Non-drug
medical costs considered by the model include RAS
Table 1
Regimen-speciﬁc input parameters.
Input parameter Panitumumab + mFOLFOX6 Bevacizumab + mFOLFOX6 Source
Biologic drug-acquisition cost €387 €278 French Health Ministry [18,19]
Chemotherapy drug-acquisition and chemotherapy/
biologic drug-administration cost (note: biologic
drug-acquisition costs are separate)
€440 €473 Weighted average DRG costs for the health collective
perspective (70% inpatient; 30% day case) from HEVA
[20]
Number of treatment cycles Estimated from the average number of observed
panitumumab, bevacizumab, and mFOLFOX6 infusions
for patients with wild-type RAS mCRC from the PEAK
trial, the projected PFS beyond the data collection
period, and the ratio of actual to observed treatments in
the data collection period
Panitumumab 19.82 –
Bevacizumab – 14.10
mFOLFOX6 12.23 10.50
Serious adverse events (incidence) Incidence of serious adverse events occurring in >2% of
patients with wild-type RAS mCRC in either treatment
arm (May 30, 2012, data cutoﬀ) from PEAK trial [9]
Pulmonary embolism 4.7% 2.5%
Diarrhoea 3.5% 1.3%
Sepsis 3.5% 1.3%
Dehydration 2.3% 0.0%
Febrile neutropenia 2.3% 2.5%
Gastroesophageal reﬂux disease 2.3% 0.0%
Pneumonia 2.3% 3.8%
Deep vein thrombosis 1.2% 3.8%
Pyrexia 1.2% 3.8%
Urinary tract infection 1.2% 2.5%
Vomiting 1.2% 2.5%
Infection 0.0% 2.5%
Intestinal perforation 0.0% 2.5%
Syncope 0.0% 2.5%
Subsequent therapy use Subsequent antitumour therapies from PEAK trial [9]
and other assumptionsAnti-EGFR + FOLFIRI – 69.3%
Bevacizumab + FOLFIRI 65.5% –
Best supportive care 34.5 30.7%
Subsequent therapy duration
Anti-EGFR + FOLFIRI Peeters et al. [21]; Giantonio et al. [22]. Reported
medians converted to means for use in the model by
assuming an exponential distribution
PFS (median) 25.65 weeks
Treatment cycles (median) 11.8
Bevacizumab + FOLFIRI
PFS (median) 31.74 weeks
Treatment cycles (median) 10.0
Resection attempts 13.6% 11.0% Resection attempts for liver metastases for patients with
wild-type RAS mCRC from the PEAK trial
Successful resection 66.7% 77.8% Successful resection (complete removal) of liver
metastases for patients with wild-type RAS mCRC from
the PEAK trial
DRG, diagnosis-related group; EGFR, epidermal growth factor receptor; FOLFIRI, leucovorin, 5-ﬂuorouracil and irinotecan; FOLFOX, leucovorin, 5-ﬂuorouracil, and oxaliplatin; mFOLFOX6,
oxaliplatin + 5-ﬂuorouracil + leucovorin; PFS, progression-free survival.
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physician visits, diagnostic tests, serious adverse events
treatment, resection, subsequent treatment and BSC
(Table 2).2.5. Utility weights
Utility weights used in the model were based on
EuroQol-5 Dimension (EQ-5D) questionnaire responses
from patients with wild-type RAS mCRC in the ﬁrst-line
PRIME (NCT00364013) clinical trial [7,32], patients
with wild-type KRAS mCRC in the second-line pani-
tumumab clinical trial [21] and BSC patients with
wild-type KRAS mCRC in the third-line panitumumab
clinical trial [6] (Table 2). For second-line and beyond,
we assumed that utility weights for patients with wild-
type RAS mCRC were similar to utility weights for
those with wild-type KRAS mCRC due to lack of bio-
marker analysis for wild-type RAS utilities in these trials
at the time of the present analysis. Utility weights were
calculated by averaging all EQ-5D responses before dis-
ease progression in each of the respective trials and
treatment lines, using the Dolan algorithm [33]. Utility
weights for patients living disease-free after a successful
resection were assumed to be equivalent to the progres-
sion-free utility weight for all patients with wild-type
RAS mCRC. Disease-recurrence utility weights were
assumed to be the average of subsequent active treat-
ment and BSC in the disease progression health state.2.6. Analyses
The model outcomes calculated for each ﬁrst-line
treatment regimen included patient survival (life-years),
quality-adjusted life-years (QALYs) and costs for
healthcare resources. Brieﬂy, QALYs are calculated as
the time (i.e. years) spent in a health state multiplied
by utility weights corresponding to patient health at that
time. Utility weights generally range from zero, repre-
senting death, to one, representing perfect health. By
adjusting survival (time) by quality of life (utility
weights), the cost-eﬀectiveness of treatments across a
range of conditions is standardised so that decision
makers can allocate resources using comparable statis-
tics, i.e. incremental cost-eﬀectiveness ratios (ICERs).
ICERs are calculated as the diﬀerence in total costs
divided by diﬀerence in total life years. In the case of this
analysis, the incremental costs per life-year and per
QALY gained were calculated. All costs were reported
in 2013 Euros, and all costs and outcomes (beneﬁts) in
the model were discounted using the suggested discount
rate in France of 4.0% per annum [34].
To test the robustness of the model methods, assump-
tions, and speciﬁc parameters, we examined the eﬀect of
using alternative methods and data sources for the model
inputs in a series of focused scenario analyses conductedaround the assumptions and methods used to calculate
drug-acquisition costs, subsequent treatment and utility
weights. We also examined the eﬀect of changing param-
eters individually as part of one-way sensitivity analyses.
In addition to one-way sensitivity analyses, a probabi-
listic sensitivity analysis was performed to examine the
eﬀects of joint uncertainty across all the parameters of
the model. The results of the probabilistic sensitivity anal-
ysis were summarised using cost-eﬀectiveness scatter plots
(not shown) and cost-eﬀectiveness acceptability curves.
3. Results
The cost-eﬀectiveness model is based on a head-to-
head clinical trial that demonstrates better eﬃcacy out-
comes for patients with wild-type RAS mCRC who
receive panitumumab plus mFOLFOX6 versus bev-
acizumab plus mFOLFOX6. Table 3 summarises the
cost-eﬀectiveness results of the deterministic (base-case)
analysis. The model projected 3.58 life-years for pani-
tumumab plus mFOLFOX6 and 2.73 life-years for bev-
acizumab plus mFOLFOX6 (both arms discounted 4%
per annum). Adjusting for quality of life, panitumumab
plus mFOLFOX6 was estimated to produce 2.68
QALYs, while bevacizumab plus mFOLFOX6 was esti-
mated to produce 2.05 QALYs (both arms discounted
4% per annum). Monoclonal antibody drug-acquisition
costs made up 40–44% of total costs modelled, with BSC
costs contributing the second greatest proportion of
costs (23–25% of total). Due to greater PFS (longer
duration of therapy) and higher drug-acquisition costs,
total drug costs were higher for panitumumab plus
mFOLFOX6 than for bevacizumab plus mFOLFOX6
(€42,843 versus €29,871). Similarly, costs for administra-
tion, chemotherapy drugs and BSC were higher for
panitumumab plus mFOLFOX6 than for bevacizumab
plus mFOLFOX6 due to longer survival.
The incremental cost per life-year gained was esti-
mated to be €26,918, and the incremental cost per
QALY gained was estimated to be €36,577. The one-
way sensitivity analysis indicated that drug-acquisition
costs, costs of BSC and costs of subsequent treatments
were the most sensitive parameters.
Scenario analysis conducted around major model
assumptions indicated that the model was robust to
alternative assumptions of PFS and OS distributions,
resection modelling and subsequent treatment following
disease progression (Table 4).
Mean net monetary beneﬁts from 10,000 simulations
of the probabilistic sensitivity analysis ranged from
€10,211 to €64,176 for panitumumab plus mFOLFOX6
and from €9106 to €50,489 for bevacizumab plus
mFOLFOX6 for willingness-to-pay thresholds ranging
from €40,000 to €60,000, respectively. The cost-eﬀective-
ness acceptability curve displayed in Fig. 4 indicates that
54.0% of simulations were below a willingness-to-pay
threshold of €40,000 and 82.5% of simulations were
Table 2
Other input parameters.
Input parameter Value Source
KRAS and RAS test €123 One KRAS (exon 2) and one KRAS (exons 3–4)/NRAS (exons 2–4) test performed. Costs
from Qjagen [23]
RAS frequency 46.2% In the NCT00364013 study, 506 out of 1096 patients randomised who had a tumour sample
available for RAS testing had wild-type RAS mCRC
FOLFOX alone drug-acquisition and
administration cost
€437 Mean costs per case for collective perspective from HEVA [20]
General practitioner oﬃce visit cost €23 General practitioner visits were assumed to occur every 4 weeks. Costs were from French
Health Insurance [24]a
Oncology specialist oﬃce visit cost €28 Visits to an oncology specialist are assumed to occur every treatment cycle (2 weeks). Costs
were from French Health Insurance [24]
Computed tomography scan cost €50 It was assumed that disease progression would be monitored every 8 weeks, similar to the
protocol from the panitumumab clinical trial
Costs were for a computed tomography scan of the abdomen and pelvis from the
Classiﬁcation Commune des Actes Me´dicaux [25]
Serious adverse events cost (hospital costs)
Pulmonary embolism €3984 Assumed similar to costs for an arterial thrombolic event from Mickisch et al. [26]
Diarrhoea €1991 Average of mean hospitalisation costs from Mickisch et al. [26] and Douillard et al. [27]
Sepsis €3954 Assumed similar to febrile neutropenia
Dehydration €3563 Hospitalisation costs from Vergnenegre et al. [28]
Febrile neutropenia €3954 Mean hospitalisation costs from Durand-Zaleski et al. [29]
Gastroesophageal reﬂux disease €3563 Assumed similar to dehydration
Pneumonia €3954 Mean hospitalisation costs from Durand-Zaleski et al. [29]
Deep vein thrombosis €1447 Mean hospitalisation costs for a venous thromboembolic event from Mickisch et al. [26]
Pyrexia €3954 Assumed similar to febrile neutropenia
Urinary tract infection €3954 Assumed similar to febrile neutropenia
Vomiting €1991 Assumed similar to diarrhoea
Infection €3954 Assumed similar to febrile neutropenia
Intestinal perforation €3984 Assumed similar to costs for an arterial thrombolic event from Mickisch et al. [26]
Syncope €3563 Assumed similar to costs of dehydration
Resection surgery and hospitalisation
cost
€14,428 HEVA [20]
Disease relapse following resection
cost per cycle
€1913 Average of subsequent therapies modelled postprogression
End-of-life cost €7653 French Health Ministry [18–19]
Best supportive care costs per cycle €564 Remak and Brazil [30] estimated the monthly costs for supportive care to be £675 per
month. This value was divided by 2 to estimate a per-cycle cost, inﬂated to 2011–2012 lb [31]
and converted to Euros (£1 = €1.15)
Utility weights
Progression free 0.821 Wild-type RAS from ﬁrst-line NCT00364013 trial
Progressive disease
Subsequent active treatment 0.782 Wild-type KRAS from second-line 20050181 trial
Best supportive care 0.681 Patients with wild-type KRAS mCRC treated with best supportive care in the third-line
20020408 trial
FOLFOX, leucovorin, 5-ﬂuorouracil and oxaliplatin.
a Scheduled physician visits did not include visits for serious adverse events treatment or management that occurred on days other than the day of
treatment administration. Also, costs of scheduled physician visits during best supportive care after disease progression were captured as part of the
best supportive care costs and were not included in these cost estimates, because the frequency of oﬃce visits was likely to be diﬀerent.
C.N. Graham et al. / European Journal of Cancer 50 (2014) 2791–2801 2797below a willingness-to-pay threshold of €60,000. Addi-
tionally, 97% of simulations performed showed pani-
tumumab plus mFOLFOX6 to be more eﬀective and
more costly or more eﬀective and less costly than bev-
acizumab plus mFOLFOX6.4. Discussion
We developed a semi-Markov model based on the
ﬁrst-line PEAK study to investigate the cost-eﬀective-
ness of panitumumab plus mFOLFOX6 compared with
bevacizumab plus mFOLFOX6 in patients withwild-type RAS mCRC. Based on the model projections,
treatment with panitumumab plus mFOLFOX6 resulted
in longer survival and greater QALYs than
bevacizumab plus mFOLFOX6. Accordingly with
increased survival, total costs for panitumumab plus
mFOLFOX6 were also greater.
To our knowledge, this is the ﬁrst cost-eﬀectiveness
publication reporting analyses for the wild-type RAS
mCRC population, and the ﬁrst head-to-head study
between panitumumab and bevacizumab using patient-
level data. Lawrence et al. [10] recently published a ﬁrst-
line cost-eﬀectiveness analysis comparing panitumumab,
Table 3
Deterministic results.
Outcome/cost category Panitumumab
+ mFOLFOX6
Bevacizumab
+ mFOLFOX6
Diﬀerence Between
Panitumumab
+ mFOLFOX6 and
Bevacizumab
+ mFOLFOX6
Outcome
Patient survival (undiscounted) 4.06 3.02 1.039
Life-years 3.58 2.73 0.846
QALYs 2.68 2.05 0.622
Cost category
RAS test €268 €0 €268
Biologic drug €42,843 €29,871 €12,972
Administration and chemotherapy drug €11,336 €9507 €1829
Toxicity treatment and management €873 €1058 €185
Physician visits €1581 €1247 €334
Monitoring for disease progression €506 €99 €407
Best supportive care €24,418 €17,140 €7278
Resection related €8823 €8006 €817
End-of-life costs €6554 €6811 €257
Total costs €97,203 €74,440 €22,763
Incremental cost-eﬀectiveness ratios of panitumumab
+ mFOLFOX6 versus bevacizumab
+ mFOLFOX6
Incremental cost per life-year gained €26,918
Incremental cost per QALY gained €36,577
mFOLFOX6, oxaliplatin + 5-ﬂuorouracil + leucovorin; QALY, quality-adjusted life-year.
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mCRC population. However, the analysis is outdated
as it does not use the current labelled population of
patients with wild-type RAS mCRC, nor does it make
use of recent informative head-to-head clinical trial
results.
The model described in this article, like all models, has
its limitations, although we feel that adequate sensitivity
and scenario analyses around modelling assumptions
have shown those limitations to result in similar conclu-
sions of value for money. The PEAK trial is a phase 2
trial with a lower number of enrolled patients
(N = 285) than a phase 3 trial. In the wild-type RAS
mCRC patient population of PEAK, the primary end-
point (PFS) was signiﬁcantly in favor of panitumumab
and a secondary end-point (OS) showed a strong trend
in terms of incremental beneﬁt (12.4 months) favouring
the panitumumab arm, despite low power to detect dif-
ferences. Our probabilistic sensitivity analysis takes
issues related to lower sample sizes into account with
its uncertainty around the treatment variable included
in the parametric survival modelling. Despite increased
uncertainty due to a lower sample size, the cost-eﬀective-
ness acceptability curves show good value for money for
panitumumab plus mFOLFOX6.
Models based on clinical trials can have inherent
limitations due to the design of the trial and the inclu-
sion criteria for patients, which may mean that the trial
population is not completely representative of ‘real
world’ clinical patients. Therefore, for our model, we
compared the clinical characteristics of the wild-typeRAS mCRC population in the bevacizumab arm of
PEAK with a recently published real-life French
mCRC patient cohort from the ETNA study.[35]
ETNA only included mCRC patients treated with bev-
acizumab and did not select by RAS tumour status.
The clinical characteristics of the PEAK bevacizumab
cohort show some diﬀerences versus the ETNA popu-
lation, but these diﬀerences likely balance each other
out from a prognostic perspective: there were no
ECOG 2 patients in PEAK versus 12% in ETNA and
median age was 60 years in PEAK versus 65 years in
ETNA; however, only 40% of patients in PEAK had
a single metastatic site versus 57% in ETNA. Patient
survival rates in PEAK versus ETNA were similar at
1 year (79% versus 80%), 2 years (59% versus 54%)
and 3 years (30% versus 29%), which supports the pro-
posal that the PEAK population can be considered
representative of the French population.
Additionally, a limitation of the PEAK trial, and the
majority of all other trials in oncology, is that most data
collection stops at the point of disease progression. Our
knowledge of subsequent treatments is limited to the
types of drugs patients received post progression. Based
on this information, we attempted to model the costs
associated with those treatments to reﬂect a real-world
treatment scenario. We did not model subsequent ther-
apy costs of the newer agents to market (e.g. aﬂibercept,
regorafenib), but we do not expect that the inclusion of
these therapies would change the conclusions of the
model given the ﬁrst-line focus of the analysis and that
cost diﬀerences would wash out between arms. Over a
Table 4
Scenario analysis results.
Alternative input parameter scenario Incremental
cost per
QALY
gained
Change
from base
case (%)
Base case analysis €36,577
Parametric survival analysis
Log–logistic PFS €40,973 12.02
Log–logistic OS €36,041 1.47
Log–logistic PFS and OS €40,169 9.82
Drug consumption
No vial wastage (vial sharing) €35,834 2.03
Wastage €37,926 3.69
Number of treatment cycles
Observed number of treatment cycles
preprogression
€30,384 16.93
Resection
No resection modelled €35,589 2.70
Subsequent therapy postprogression
All patients receive BSC
postprogression
€50,390 37.76
No drug, BSC, or end-of-life costs
postprogression
€38,310 4.74
BSC, best supportive care; OS, overall survival; PFS, progression-free
survival; QALY, quality-adjusted life-year.
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analyses, conclusions of the model did not change.
While our analysis focused on a ﬁrst-line treatment
comparison between an anti-EGFR, panitumumab,
and an anti-VEGF, bevacizumab, it would be of interest
to decision makers to examine costs and outcomes
within the anti-EGFR class. To date, no ﬁrst-line trials
have been conducted between panitumumab and cetux-
imab. However, the ASPECCT trial examined these
treatments as monotherapies in the third-line setting
[36]. In the KRAS population, PFS and OS hazard
ratios were 1.00 (95% conﬁdence interval (CI) 0.88,
1.14) and 0.97 (95% CI 0.84, 1.11), respectively. ThereFig. 4. Cost-eﬀectiveness acceptability curve. CE, cost-eﬀectivenare no RAS available data for this trial. If we were to
assume equivalent eﬃcacy in the ﬁrst-line setting and
modelled both treatments, we would expect, for cetux-
imab relative to panitumumab, higher administration
costs (cetuximab must be administered weekly and pani-
tumumab is administered every 2 weeks), higher costs
due to infusion reactions (rates of any grade infusion
reaction were 14% with cetuximab versus 3% with pani-
tumumab in ASPECCT) and higher premedication costs
(as premedication for cetuximab is required to reduce
infusion reactions). Additional modelling taking into
account the potential uncertainty of PFS and OS diﬀer-
ences between the products would be needed to conﬁrm
this assumption.
Utility weights for our model were estimated from
other panitumumab trials that included the EQ-5D as
a part of data collection. In some of these trials, wild-
type RAS data were not available at the time of the pres-
ent analysis. In examining utility weights calculated
from the PRIME trial with both wild-type KRAS and
RAS biomarkers, we found little diﬀerence in progres-
sion-free utility weights between the groups. Addition-
ally, our model assumes no diﬀerence in utility weights
between treatments, so any change to the utility weights
would have equal impact on both treatments compared.
Finally, the basis of this analysis assumes that treat-
ment of mCRC with ﬁrst-line agents is acceptable from
the payer perspective. This is indeed the case in a major-
ity of countries. However given the high total costs of
treatment, an analysis that examines the cost-eﬀective-
ness of ﬁrst-line mCRC treatment compared with no
treatment (i.e. best supportive care) may be of interest
to decision makers and patients in areas that have not
approved ﬁrst-line mCRC treatment for reimbursement.
Based on results of this model, panitumumab plus
mFOLFOX6 represents good value for money com-
pared with a current standard of care bevacizumab plus
mFOLFOX6 and, with a willingness-to-pay rangingess; mFOLFOX6, oxaliplatin + 5-ﬂuorouracil + leucovorin.
2800 C.N. Graham et al. / European Journal of Cancer 50 (2014) 2791–2801from €40,000 to €60,000 can be considered cost-eﬀective
in ﬁrst-line treatment of patients with wild-type RAS
mCRC. Future research extending treatment comparisons
to other active regimens will produce a clearer picture of
the cost eﬀectiveness of treatments for patients with
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